You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEnoxaparin
Accession NumberDB01225  (APRD00068)
TypeSmall Molecule
GroupsApproved
DescriptionEnoxaparin is a low molecular weight heparin. Enoxaparin is used to prevent and treat deep vein thrombosis or pulmonary embolism, and is given as a subcutaneous injection. Enoxaparin binds to and accelerates the activity of antithrombin III. By activating antithrombin III, enoxaparin preferentially potentiates the inhibition of coagulation factors Xa and IIa. Factor Xa catalyzes the conversion of prothrombin to thrombin, so enoxaparin's inhibition of this process results in decreased thrombin and ultimately the prevention of fibrin clot formation. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
Structure
Thumb
Synonyms
Enoxaparin sodium
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Enoxaparin SodiumInjection150 mg/mLSubcutaneousWinthrop U.S.2011-10-03Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2015-02-20Not applicableUs
Enoxaparin SodiumInjection150 mg/mLSubcutaneousFresenius Kabi USA, LLC2015-02-20Not applicableUs
Enoxaparin SodiumInjection80 mg/.8mLSubcutaneousWinthrop U.S.2011-10-03Not applicableUs
Enoxaparin SodiumInjection300 mg/3mLSubcutaneousWinthrop U.S.2011-10-03Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2015-02-20Not applicableUs
Enoxaparin SodiumInjection30 mg/.3mLSubcutaneousWinthrop U.S.2011-10-03Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousWinthrop U.S.2011-10-03Not applicableUs
Enoxaparin SodiumInjection300 mg/3mLSubcutaneousFresenius Kabi USA, LLC2015-02-20Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2015-02-20Not applicableUs
Enoxaparin SodiumInjection40 mg/.4mLSubcutaneousWinthrop U.S.2011-10-03Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2015-02-20Not applicableUs
Enoxaparin SodiumInjection120 mg/.8mLSubcutaneousWinthrop U.S.2011-10-03Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousFresenius Kabi USA, LLC2015-02-20Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2015-02-20Not applicableUs
Enoxaparin SodiumInjection60 mg/.6mLSubcutaneousWinthrop U.S.2011-10-03Not applicableUs
LovenoxInjection40 mg/.4mLIntravenous; SubcutaneousCardinal Health1993-03-29Not applicableUs
LovenoxInjection150 mg/mLIntravenous; SubcutaneousSanofi Aventis U.S. Llc1993-03-29Not applicableUs
LovenoxInjection300 mg/3mLIntravenous; SubcutaneousSanofi Aventis U.S. Llc1993-03-29Not applicableUs
LovenoxInjection40 mg/.4mLIntravenous; SubcutaneousCardinal Health1993-03-29Not applicableUs
LovenoxInjection40 mg/.4mLIntravenous; SubcutaneousSanofi Aventis U.S. Llc1993-03-29Not applicableUs
LovenoxInjection80 mg/.8mLIntravenous; SubcutaneousSanofi Aventis U.S. Llc1993-03-29Not applicableUs
LovenoxInjection60 mg/.6mLIntravenous; SubcutaneousPhysicians Total Care, Inc.2006-05-17Not applicableUs
LovenoxInjection30 mg/.3mLIntravenous; SubcutaneousSanofi Aventis U.S. Llc1993-03-29Not applicableUs
LovenoxInjection60 mg/.6mLIntravenous; SubcutaneousCardinal Health1993-03-29Not applicableUs
LovenoxInjection30 mg/.3mLIntravenous; SubcutaneousCardinal Health1993-03-29Not applicableUs
LovenoxInjection30 mg/.3mLIntravenous; SubcutaneousSanofi Aventis U.S. Llc1993-03-29Not applicableUs
LovenoxInjection60 mg/.6mLIntravenous; SubcutaneousCardinal Health1993-03-29Not applicableUs
LovenoxSolution60 mgSubcutaneousSanofi Aventis Canada Inc2012-11-13Not applicableCanada
LovenoxInjection60 mg/.6mLIntravenous; SubcutaneousSanofi Aventis U.S. Llc1993-03-29Not applicableUs
LovenoxInjection100 mg/mLIntravenous; SubcutaneousSanofi Aventis U.S. Llc1993-03-29Not applicableUs
LovenoxInjection100 mg/mLIntravenous; SubcutaneousPhysicians Total Care, Inc.2007-11-29Not applicableUs
LovenoxSolution30 mgSubcutaneousSanofi Aventis Canada Inc1993-12-31Not applicableCanada
LovenoxInjection300 mg/3mLIntravenous; SubcutaneousSanofi Aventis U.S. Llc1993-03-29Not applicableUs
LovenoxInjection80 mg/.8mLIntravenous; SubcutaneousCardinal Health1993-03-29Not applicableUs
LovenoxInjection40 mg/.4mLIntravenous; SubcutaneousSanofi Aventis U.S. Llc1993-03-29Not applicableUs
LovenoxInjection80 mg/.8mLIntravenous; SubcutaneousPhysicians Total Care, Inc.2004-07-28Not applicableUs
LovenoxInjection80 mg/.8mLIntravenous; SubcutaneousSanofi Aventis U.S. Llc1993-03-29Not applicableUs
LovenoxInjection80 mg/.8mLIntravenous; SubcutaneousCardinal Health1993-03-29Not applicableUs
LovenoxSolution80 mgSubcutaneousSanofi Aventis Canada Inc2012-09-11Not applicableCanada
LovenoxInjection120 mg/.8mLIntravenous; SubcutaneousSanofi Aventis U.S. Llc1993-03-29Not applicableUs
LovenoxInjection120 mg/.8mLIntravenous; SubcutaneousPhysicians Total Care, Inc.2007-12-04Not applicableUs
LovenoxInjection120 mg/.8mLIntravenous; SubcutaneousSanofi Aventis U.S. Llc1993-03-29Not applicableUs
LovenoxInjection100 mg/mLIntravenous; SubcutaneousCardinal Health1993-03-29Not applicableUs
LovenoxInjection60 mg/.6mLIntravenous; SubcutaneousSanofi Aventis U.S. Llc1993-03-29Not applicableUs
LovenoxInjection40 mg/.4mLIntravenous; SubcutaneousPhysicians Total Care, Inc.2005-10-06Not applicableUs
LovenoxInjection100 mg/mLIntravenous; SubcutaneousSanofi Aventis U.S. Llc1993-03-29Not applicableUs
LovenoxInjection100 mg/mLIntravenous; SubcutaneousCardinal Health1993-03-29Not applicableUs
LovenoxSolution100 mgSubcutaneousSanofi Aventis Canada Inc2012-09-21Not applicableCanada
LovenoxInjection150 mg/mLIntravenous; SubcutaneousSanofi Aventis U.S. Llc1993-03-29Not applicableUs
LovenoxInjection30 mg/.3mLIntravenous; SubcutaneousCardinal Health1993-03-29Not applicableUs
LovenoxSolution40 mgSubcutaneousSanofi Aventis Canada Inc1998-06-02Not applicableCanada
Lovenox HpSolution120 mgSubcutaneousSanofi Aventis Canada Inc2002-05-21Not applicableCanada
Lovenox HpSolution150 mgSubcutaneousSanofi Aventis Canada Inc2012-12-07Not applicableCanada
Lovenox HpSolution90 mgSubcutaneousSanofi Aventis Canada IncNot applicableNot applicableCanada
Lovenox With Preservative 300mg/3mlSolution100 mgIntravenous; SubcutaneousSanofi Aventis Canada Inc1998-01-21Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2010-07-23Not applicableUs
Enoxaparin SodiumInjection120 mg/.8mLSubcutaneousWatson Pharma, Inc.2012-01-27Not applicableUs
Enoxaparin SodiumInjection150 mg/mLSubcutaneousAmphastar Pharmaceuticals, Inc.2011-09-19Not applicableUs
Enoxaparin SodiumInjection, solution150 mg/mLIntravenous; SubcutaneousTeva Parenteral Medicines, Inc.2014-09-26Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2010-07-23Not applicableUs
Enoxaparin SodiumInjection150 mg/mLSubcutaneousAmphastar Pharmaceuticals, Inc.2011-09-19Not applicableUs
Enoxaparin SodiumInjection150 mg/mLSubcutaneousSandoz Inc2010-07-23Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousAmphastar Pharmaceuticals, Inc.2011-09-19Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2010-07-23Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousSandoz Inc2010-07-23Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousAmphastar Pharmaceuticals, Inc.2011-09-19Not applicableUs
Enoxaparin SodiumInjection, solution100 mg/mLIntravenous; SubcutaneousTeva Parenteral Medicines, Inc.2014-09-26Not applicableUs
Enoxaparin SodiumInjection60 mg/.6mLSubcutaneousWatson Pharma, Inc.2012-01-27Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2010-07-23Not applicableUs
Enoxaparin SodiumInjection150 mg/mLSubcutaneousWatson Pharma, Inc.2012-01-27Not applicableUs
Enoxaparin SodiumInjection150 mg/mLSubcutaneousAmphastar Pharmaceuticals, Inc.2011-09-19Not applicableUs
Enoxaparin SodiumInjection, solution30 mg/.3mLIntravenous; SubcutaneousTeva Parenteral Medicines, Inc.2014-09-26Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2010-07-23Not applicableUs
Enoxaparin SodiumInjection150 mg/mLSubcutaneousSandoz Inc2010-07-23Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousAmphastar Pharmaceuticals, Inc.2011-09-19Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2010-07-23Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousSandoz Inc2010-07-23Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousAmphastar Pharmaceuticals, Inc.2011-09-19Not applicableUs
Enoxaparin SodiumInjection, solution120 mg/.8mLIntravenous; SubcutaneousTeva Parenteral Medicines, Inc.2014-09-26Not applicableUs
Enoxaparin SodiumInjection80 mg/.8mLSubcutaneousWatson Pharma, Inc.2012-01-27Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousAmphastar Pharmaceuticals, Inc.2011-09-19Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2010-07-23Not applicableUs
Enoxaparin SodiumInjection100 mg/mLIntravenous; SubcutaneousSandoz Inc2012-04-232017-11-30Us
Enoxaparin SodiumInjection100 mg/mLSubcutaneousAmphastar Pharmaceuticals, Inc.2011-09-19Not applicableUs
Enoxaparin SodiumInjection, solution40 mg/.4mLIntravenous; SubcutaneousTeva Parenteral Medicines, Inc.2014-09-26Not applicableUs
Enoxaparin SodiumInjection30 mg/.3mLSubcutaneousWatson Pharma, Inc.2012-01-27Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousAmphastar Pharmaceuticals, Inc.2011-09-19Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2010-07-23Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousSandoz Inc2010-07-23Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousAmphastar Pharmaceuticals, Inc.2011-09-19Not applicableUs
Enoxaparin SodiumInjection, solution80 mg/.8mLIntravenous; SubcutaneousTeva Parenteral Medicines, Inc.2014-09-26Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousWatson Pharma, Inc.2012-01-27Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousAmphastar Pharmaceuticals, Inc.2011-09-19Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2010-07-23Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousSandoz Inc2010-07-23Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousAmphastar Pharmaceuticals, Inc.2011-09-19Not applicableUs
Enoxaparin SodiumInjection, solution60 mg/.6mLIntravenous; SubcutaneousTeva Parenteral Medicines, Inc.2014-09-26Not applicableUs
Enoxaparin SodiumInjection40 mg/.4mLSubcutaneousWatson Pharma, Inc.2012-01-27Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousSandoz Inc2010-07-23Not applicableUs
Enoxaparin SodiumInjection150 mg/mLSubcutaneousAmphastar Pharmaceuticals, Inc.2011-09-19Not applicableUs
Enoxaparin SodiumInjection100 mg/mLSubcutaneousCardinal Health2010-07-23Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ClexaneNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII8NZ41MIK1O
CAS number9005-49-6
WeightNot Available
Chemical FormulaC26H42N2O37S5
InChI KeyHTTJABKRGRZYRN-UHFFFAOYSA-N
InChINot Available
IUPAC NameNot Available
SMILESNot Available
Pharmacology
IndicationFor the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism, and also for the prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, when concurrently administered with aspirin.
Structured Indications
PharmacodynamicsEnoxaparin is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from 3800 to 5000 daltons. Enoxaparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Enoxaparin is a well known and commonly used anticoagulant which has antithrombotic properties. Enoxaparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Enoxaparin acts at multiple sites in the normal coagulation system. Small amounts of enoxaparin in combination with antithrombin III (enoxaparin cofactor) can inhibit thrombosis by inactivating activated Factor X and inhibiting the conversion of prothrombin to thrombin. Once active thrombosis has developed, larger amounts of enoxaparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Enoxaparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Its use should be avoided in patients with a creatinine clearance less than 20mL/min. In these patients, unfractionated heparin should only be used. As for monitoring, active partial thromboplastin time (aPTT) will only increase at high doses of low molecular weight heparins (LMWH). Therefore, monitoring aPTT is not recommended. However, anti-Xa activity can be measured to monitor the efficacy of the LMWH.
Mechanism of actionThe mechanism of action of enoxaparin is antithrombin-dependent. It acts mainly by accelerating the rate of the neutralization of certain activated coagulation factors by antithrombin, but other mechanisms may also be involved. The antithrombotic effect of enoxaparin is well correlated to the inhibition of factor Xa. Enoxaparin interacts with Antithrombin III, Prothrombin and Factor X. Enoxaparin binds to and accelerates the activity of antithrombin III. By activating antithrombin III, enoxaparin preferentially potentiates the inhibition of coagulation factors Xa and IIa.
TargetKindPharmacological actionActionsOrganismUniProt ID
Antithrombin-IIIProteinyes
potentiator
HumanP01008 details
Coagulation factor XProteinyes
inhibitor
HumanP00742 details
Related Articles
AbsorptionMean absolute bioavailability of enoxaparin, after 1.5 mg/kg given subcutaneously, based on anti-Factor Xa activity is approximately 100% in healthy volunteers.
Volume of distribution
  • 4.3 L
Protein binding80% bound-albumin
Metabolism

Undergoes desulfation and polymerization via the liver

Route of eliminationEnoxaparin sodium is primarily metabolized in the liver by desulfation and/or depolymerization to lower molecular weight species with much reduced biological potency. Renal clearance of active fragments represents about 10% of the administered dose and total renal excretion of active and non-active fragments 40% of the dose.
Half life4.5 hours
ClearanceNot Available
ToxicityMouse, median lethal dose greater than 5000 mg/kg. Another side effect is heparin induced thrombocytopenia (HIT syndrome). HIT is caused by an immunological reaction that makes platelets form clots within the blood vessels, thereby using up coagulation factors.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbciximabAbciximab may increase the anticoagulant activities of Enoxaparin.Approved
AceclofenacAceclofenac may increase the anticoagulant activities of Enoxaparin.Approved
AcenocoumarolEnoxaparin may increase the anticoagulant activities of Acenocoumarol.Approved
AcetovanilloneAcetovanillone may increase the anticoagulant activities of Enoxaparin.Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
AdapaleneAdapalene may increase the anticoagulant activities of Enoxaparin.Approved
AliskirenEnoxaparin may increase the hyperkalemic activities of Aliskiren.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Allylestrenol.Approved
AlprostadilAlprostadil may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Enoxaparin.Approved
AltrenogestThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Altrenogest.Vet Approved
ALX-0081ALX-0081 may increase the anticoagulant activities of Enoxaparin.Investigational
AmilorideEnoxaparin may increase the hyperkalemic activities of Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Enoxaparin.Approved
AnagrelideAnagrelide may increase the anticoagulant activities of Enoxaparin.Approved
AncrodEnoxaparin may increase the anticoagulant activities of Ancrod.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Enoxaparin.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Enoxaparin.Approved
AntipyrineAntipyrine may increase the anticoagulant activities of Enoxaparin.Approved
Antithrombin III humanEnoxaparin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Enoxaparin.Approved
ApremilastApremilast may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
AprotininThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinArdeparin may increase the anticoagulant activities of Enoxaparin.Approved, Withdrawn
ArgatrobanArgatroban may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Enoxaparin.Investigational
AzapropazoneAzapropazone may increase the anticoagulant activities of Enoxaparin.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Enoxaparin.Approved
Azilsartan medoxomilEnoxaparin may increase the hyperkalemic activities of Azilsartan medoxomil.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Enoxaparin.Approved, Investigational
BatroxobinBatroxobin may increase the anticoagulant activities of Enoxaparin.Experimental
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Enoxaparin.Approved, Investigational
BecaplerminBecaplermin may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
BemiparinBemiparin may increase the anticoagulant activities of Enoxaparin.Approved
BenazeprilEnoxaparin may increase the hyperkalemic activities of Benazepril.Approved, Investigational
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Enoxaparin.Withdrawn
BeraprostBeraprost may increase the anticoagulant activities of Enoxaparin.Investigational
Betulinic AcidBetulinic Acid may increase the anticoagulant activities of Enoxaparin.Investigational
BivalirudinBivalirudin may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
BromfenacBromfenac may increase the anticoagulant activities of Enoxaparin.Approved
BucillamineBucillamine may increase the anticoagulant activities of Enoxaparin.Investigational
ButylphthalideButylphthalide may increase the anticoagulant activities of Enoxaparin.Investigational
CanagliflozinEnoxaparin may increase the hyperkalemic activities of Canagliflozin.Approved
CandesartanEnoxaparin may increase the hyperkalemic activities of Candesartan.Approved
CandoxatrilEnoxaparin may increase the hyperkalemic activities of Candoxatril.Experimental
CangrelorCangrelor may increase the anticoagulant activities of Enoxaparin.Approved
CaptoprilEnoxaparin may increase the hyperkalemic activities of Captopril.Approved
CarprofenCarprofen may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved, Withdrawn
CastanospermineCastanospermine may increase the anticoagulant activities of Enoxaparin.Experimental
CelecoxibCelecoxib may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
CertoparinEnoxaparin may increase the anticoagulant activities of Certoparin.Approved
ChloroquineChloroquine may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Enoxaparin.Withdrawn
CilazaprilEnoxaparin may increase the hyperkalemic activities of Cilazapril.Approved
CilostazolCilostazol may increase the anticoagulant activities of Enoxaparin.Approved
Citric AcidEnoxaparin may increase the anticoagulant activities of Citric Acid.Nutraceutical, Vet Approved
ClonixinClonixin may increase the anticoagulant activities of Enoxaparin.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Enoxaparin.Approved, Nutraceutical
CollagenaseThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Collagenase.Approved
Conjugated Equine EstrogensConjugated Equine Estrogens may decrease the anticoagulant activities of Enoxaparin.Approved
CurcuminCurcumin may increase the anticoagulant activities of Enoxaparin.Investigational
D-LimoneneD-Limonene may increase the anticoagulant activities of Enoxaparin.Investigational
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Enoxaparin.Approved
DalteparinEnoxaparin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidEnoxaparin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DasatinibDasatinib may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Deoxycholic Acid.Approved
dersalazinedersalazine may increase the anticoagulant activities of Enoxaparin.Investigational
DesirudinEnoxaparin may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Enoxaparin.Investigational
DesogestrelThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Desogestrel.Approved
DextranEnoxaparin may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Enoxaparin may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Enoxaparin may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Enoxaparin may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacDiclofenac may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
DicoumarolDicoumarol may increase the anticoagulant activities of Enoxaparin.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Enoxaparin.Approved
DienogestThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Dienogest.Approved
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Enoxaparin.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Enoxaparin.Approved
DipyridamoleDipyridamole may increase the anticoagulant activities of Enoxaparin.Approved
DitazoleDitazole may increase the anticoagulant activities of Enoxaparin.Approved, Withdrawn
DrospirenoneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Enoxaparin.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Enoxaparin.Approved
DuvelisibDuvelisib may increase the anticoagulant activities of Enoxaparin.Investigational
DydrogesteroneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Dydrogesterone.Approved, Withdrawn
E6201E6201 may increase the anticoagulant activities of Enoxaparin.Investigational
EbselenEbselen may increase the anticoagulant activities of Enoxaparin.Investigational
Edetic AcidEdetic Acid may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Enoxaparin.Approved
EnalaprilEnoxaparin may increase the hyperkalemic activities of Enalapril.Approved, Vet Approved
EnalaprilatEnoxaparin may increase the hyperkalemic activities of Enalaprilat.Approved
EpinastineEpinastine may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Enoxaparin.Approved
EplerenoneEnoxaparin may increase the hyperkalemic activities of Eplerenone.Approved
eplivanserineeplivanserine may increase the anticoagulant activities of Enoxaparin.Investigational
EpoprostenolEpoprostenol may increase the anticoagulant activities of Enoxaparin.Approved
EprosartanEnoxaparin may increase the hyperkalemic activities of Eprosartan.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
EstradiolEstradiol may decrease the anticoagulant activities of Enoxaparin.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Enoxaparin.Approved, Vet Approved
EstroneEstrone may decrease the anticoagulant activities of Enoxaparin.Approved
EtanerceptEtanercept may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Enoxaparin.Approved
Ethyl biscoumacetateEnoxaparin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Ethynodiol diacetate.Approved
EtodolacEtodolac may increase the anticoagulant activities of Enoxaparin.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Enoxaparin.Approved
EtonogestrelThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibEtoricoxib may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Enoxaparin.Approved
exisulindexisulind may increase the anticoagulant activities of Enoxaparin.Investigational
FenbufenFenbufen may increase the anticoagulant activities of Enoxaparin.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Enoxaparin.Approved
FibrinolysinFibrinolysin may increase the anticoagulant activities of Enoxaparin.Approved
FloctafenineFloctafenine may increase the anticoagulant activities of Enoxaparin.Approved, Withdrawn
FluindioneEnoxaparin may increase the anticoagulant activities of Fluindione.Investigational
FlunixinFlunixin may increase the anticoagulant activities of Enoxaparin.Vet Approved
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
FondaparinuxEnoxaparin may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumFondaparinux sodium may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
ForasartanEnoxaparin may increase the hyperkalemic activities of Forasartan.Experimental
FosinoprilEnoxaparin may increase the hyperkalemic activities of Fosinopril.Approved
GabexateEnoxaparin may increase the anticoagulant activities of Gabexate.Investigational
GenisteinGenistein may decrease the anticoagulant activities of Enoxaparin.Investigational
GestodeneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Gestodene.Approved
GestrinoneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Gestrinone.Approved
HeminHemin may increase the anticoagulant activities of Enoxaparin.Approved
HeparinHeparin may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
HexestrolHexestrol may decrease the anticoagulant activities of Enoxaparin.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Enoxaparin.Investigational
HirulogEnoxaparin may increase the anticoagulant activities of Hirulog.Experimental
HMPL-004HMPL-004 may increase the anticoagulant activities of Enoxaparin.Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Hydroxyprogesterone caproate.Approved
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Enoxaparin.Approved
IbudilastIbudilast may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Enoxaparin.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Enoxaparin.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Enoxaparin.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Enoxaparin.Approved, Nutraceutical
idraparinuxEnoxaparin may increase the anticoagulant activities of idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Enoxaparin.Approved, Withdrawn
IloprostIloprost may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
ImidaprilEnoxaparin may increase the hyperkalemic activities of Imidapril.Investigational
IndobufenIndobufen may increase the anticoagulant activities of Enoxaparin.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Enoxaparin.Withdrawn
IrbesartanEnoxaparin may increase the hyperkalemic activities of Irbesartan.Approved, Investigational
IsoxicamIsoxicam may increase the anticoagulant activities of Enoxaparin.Withdrawn
Kct 0809Kct 0809 may increase the anticoagulant activities of Enoxaparin.Investigational
KebuzoneKebuzone may increase the anticoagulant activities of Enoxaparin.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Enoxaparin.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
KetorolacKetorolac may increase the anticoagulant activities of Enoxaparin.Approved
LeflunomideLeflunomide may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
LepirudinLepirudin may increase the anticoagulant activities of Enoxaparin.Approved
LevonorgestrelThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Enoxaparin.Approved
LisinoprilEnoxaparin may increase the hyperkalemic activities of Lisinopril.Approved, Investigational
LisofyllineLisofylline may increase the anticoagulant activities of Enoxaparin.Investigational
LornoxicamLornoxicam may increase the anticoagulant activities of Enoxaparin.Approved
LosartanEnoxaparin may increase the hyperkalemic activities of Losartan.Approved
LoxoprofenLoxoprofen may increase the anticoagulant activities of Enoxaparin.Approved
LumiracoxibLumiracoxib may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
LynestrenolThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Lynestrenol.Investigational
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Enoxaparin.Approved
MasoprocolMasoprocol may increase the anticoagulant activities of Enoxaparin.Approved
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Enoxaparin.Approved
Megestrol acetateThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Megestrol acetate.Approved, Vet Approved
MeloxicamMeloxicam may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Enoxaparin.Approved
MestranolMestranol may decrease the anticoagulant activities of Enoxaparin.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Enoxaparin.Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Enoxaparin.Experimental
MilrinoneMilrinone may increase the anticoagulant activities of Enoxaparin.Approved
MizoribineMizoribine may increase the anticoagulant activities of Enoxaparin.Investigational
MoexiprilEnoxaparin may increase the hyperkalemic activities of Moexipril.Approved
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Enoxaparin.Approved
NabumetoneNabumetone may increase the anticoagulant activities of Enoxaparin.Approved
NadroparinEnoxaparin may increase the anticoagulant activities of Nadroparin.Approved
NafamostatNafamostat may increase the anticoagulant activities of Enoxaparin.Investigational
NaftifineNaftifine may increase the anticoagulant activities of Enoxaparin.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Enoxaparin.Investigational
NaproxenNaproxen may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
NCX 4016NCX 4016 may increase the anticoagulant activities of Enoxaparin.Investigational
NepafenacNepafenac may increase the anticoagulant activities of Enoxaparin.Approved
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Enoxaparin.Approved
NimesulideNimesulide may increase the anticoagulant activities of Enoxaparin.Approved, Withdrawn
NintedanibThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Nintedanib.Approved
NitroaspirinNitroaspirin may increase the anticoagulant activities of Enoxaparin.Investigational
NomegestrolThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Norethisterone.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Obinutuzumab.Approved
OlmesartanEnoxaparin may increase the hyperkalemic activities of Olmesartan.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Enoxaparin.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Enoxaparin.Approved
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Omacetaxine mepesuccinate.Approved
OmapatrilatEnoxaparin may increase the hyperkalemic activities of Omapatrilat.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Enoxaparin.Approved
OrgoteinOrgotein may increase the anticoagulant activities of Enoxaparin.Vet Approved
OtamixabanEnoxaparin may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Enoxaparin.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Enoxaparin.Withdrawn
PaliferminThe serum concentration of Palifermin can be increased when it is combined with Enoxaparin.Approved
ParecoxibParecoxib may increase the anticoagulant activities of Enoxaparin.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Enoxaparin.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Enoxaparin.Approved
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
PerindoprilEnoxaparin may increase the hyperkalemic activities of Perindopril.Approved
PhenindionePhenindione may increase the anticoagulant activities of Enoxaparin.Approved
PhenprocoumonPhenprocoumon may increase the anticoagulant activities of Enoxaparin.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
PimecrolimusPimecrolimus may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
PirfenidonePirfenidone may increase the anticoagulant activities of Enoxaparin.Investigational
PiroxicamPiroxicam may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
PlasminPlasmin may increase the anticoagulant activities of Enoxaparin.Investigational
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Enoxaparin.Approved
PrasugrelPrasugrel may increase the anticoagulant activities of Enoxaparin.Approved
ProgesteroneThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Progesterone.Approved, Vet Approved
PromestrienePromestriene may decrease the anticoagulant activities of Enoxaparin.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Enoxaparin.Approved
Protein CEnoxaparin may increase the anticoagulant activities of Protein C.Approved
Protein S humanEnoxaparin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeEnoxaparin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299PTC299 may increase the anticoagulant activities of Enoxaparin.Investigational
QuinaprilEnoxaparin may increase the hyperkalemic activities of Quinapril.Approved, Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Enoxaparin.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Enoxaparin.Investigational
RamiprilEnoxaparin may increase the hyperkalemic activities of Ramipril.Approved
RescinnamineEnoxaparin may increase the hyperkalemic activities of Rescinnamine.Approved
ResveratrolResveratrol may increase the anticoagulant activities of Enoxaparin.Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Enoxaparin.Approved
ReviparinEnoxaparin may increase the anticoagulant activities of Reviparin.Approved
RidogrelRidogrel may increase the anticoagulant activities of Enoxaparin.Approved
RivaroxabanEnoxaparin may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibRofecoxib may increase the anticoagulant activities of Enoxaparin.Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
S EquolS Equol may decrease the anticoagulant activities of Enoxaparin.Investigational
SacubitrilEnoxaparin may increase the hyperkalemic activities of Sacubitril.Approved
SalicylamideSalicylamide may increase the anticoagulant activities of Enoxaparin.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Enoxaparin.Approved
SaprisartanEnoxaparin may increase the hyperkalemic activities of Saprisartan.Experimental
SaralasinEnoxaparin may increase the hyperkalemic activities of Saralasin.Investigational
SCH-530348SCH-530348 may increase the anticoagulant activities of Enoxaparin.Investigational
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Enoxaparin.Investigational
SelexipagSelexipag may increase the anticoagulant activities of Enoxaparin.Approved
SeratrodastSeratrodast may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Enoxaparin.Approved, Vet Approved
SpiraprilEnoxaparin may increase the hyperkalemic activities of Spirapril.Approved
SpironolactoneEnoxaparin may increase the hyperkalemic activities of Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Enoxaparin.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Enoxaparin.Approved
SugammadexSugammadex may increase the anticoagulant activities of Enoxaparin.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Enoxaparin.Approved
SulindacSulindac may increase the anticoagulant activities of Enoxaparin.Approved
SulodexideEnoxaparin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenSuprofen may increase the anticoagulant activities of Enoxaparin.Approved, Withdrawn
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Enoxaparin.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Enoxaparin.Approved
TasosartanEnoxaparin may increase the hyperkalemic activities of Tasosartan.Approved
TelmisartanEnoxaparin may increase the hyperkalemic activities of Telmisartan.Approved, Investigational
TemocaprilEnoxaparin may increase the hyperkalemic activities of Temocapril.Experimental, Investigational
TenecteplaseTenecteplase may increase the anticoagulant activities of Enoxaparin.Approved
TenoxicamTenoxicam may increase the anticoagulant activities of Enoxaparin.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Enoxaparin.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Enoxaparin.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Enoxaparin.Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Enoxaparin.Approved
TiboloneTibolone may increase the anticoagulant activities of Enoxaparin.Approved
TicagrelorTicagrelor may increase the anticoagulant activities of Enoxaparin.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Enoxaparin.Approved
TinoridineTinoridine may increase the anticoagulant activities of Enoxaparin.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Enoxaparin.Approved
TipranavirTipranavir may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Enoxaparin.Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Enoxaparin.Approved
TolmetinTolmetin may increase the anticoagulant activities of Enoxaparin.Approved
TositumomabThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Tositumomab.Approved
TrandolaprilEnoxaparin may increase the hyperkalemic activities of Trandolapril.Approved
TranilastTranilast may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Enoxaparin.Approved
TreprostinilTreprostinil may increase the anticoagulant activities of Enoxaparin.Approved, Investigational
TriamtereneEnoxaparin may increase the hyperkalemic activities of Triamterene.Approved
TriflusalTriflusal may increase the anticoagulant activities of Enoxaparin.Approved
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Enoxaparin.Approved
UrokinaseUrokinase may increase the anticoagulant activities of Enoxaparin.Approved, Investigational, Withdrawn
ValdecoxibValdecoxib may increase the anticoagulant activities of Enoxaparin.Investigational, Withdrawn
ValsartanEnoxaparin may increase the hyperkalemic activities of Valsartan.Approved, Investigational
Vitamin EVitamin E may increase the anticoagulant activities of Enoxaparin.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Enoxaparin.Approved
WarfarinWarfarin may increase the anticoagulant activities of Enoxaparin.Approved
XimelagatranEnoxaparin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Ym150Enoxaparin may increase the anticoagulant activities of Ym150.Investigational
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Enoxaparin.Approved
ZeranolZeranol may decrease the anticoagulant activities of Enoxaparin.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Enoxaparin.Approved, Investigational, Withdrawn
ZomepiracZomepirac may increase the anticoagulant activities of Enoxaparin.Withdrawn
Food Interactions
  • Avoid danshen, dong quai, evening primrose oil, gingko, policosanol, willow bark
References
Synthesis Reference

Jorgen I. Nielsen, “Process of using light absorption to control enzymatic depolymerization of heparin to produce low molecular weight heparin.” U.S. Patent US5106734, issued May, 1981.

US5106734
General ReferencesNot Available
External Links
ATC CodesB01AB05
AHFS Codes
  • 20:12.04.16
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (1.44 MB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9215
Blood Brain Barrier-0.8366
Caco-2 permeable-0.6496
P-glycoprotein substrateNon-substrate0.698
P-glycoprotein inhibitor INon-inhibitor0.5818
P-glycoprotein inhibitor IINon-inhibitor0.9771
Renal organic cation transporterNon-inhibitor0.9454
CYP450 2C9 substrateNon-substrate0.6694
CYP450 2D6 substrateNon-substrate0.8196
CYP450 3A4 substrateNon-substrate0.5842
CYP450 1A2 substrateNon-inhibitor0.8157
CYP450 2C9 inhibitorNon-inhibitor0.771
CYP450 2D6 inhibitorNon-inhibitor0.8869
CYP450 2C19 inhibitorNon-inhibitor0.7655
CYP450 3A4 inhibitorNon-inhibitor0.9194
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9232
Ames testNon AMES toxic0.5957
CarcinogenicityNon-carcinogens0.694
BiodegradationNot ready biodegradable0.851
Rat acute toxicity2.3846 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9589
hERG inhibition (predictor II)Non-inhibitor0.7157
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
InjectionSubcutaneous100 mg/mL
InjectionSubcutaneous120 mg/.8mL
InjectionSubcutaneous150 mg/mL
InjectionSubcutaneous30 mg/.3mL
InjectionSubcutaneous300 mg/3mL
InjectionSubcutaneous40 mg/.4mL
InjectionSubcutaneous60 mg/.6mL
InjectionSubcutaneous80 mg/.8mL
Injection, solutionIntravenous; Subcutaneous100 mg/mL
Injection, solutionIntravenous; Subcutaneous120 mg/.8mL
Injection, solutionIntravenous; Subcutaneous150 mg/mL
Injection, solutionIntravenous; Subcutaneous30 mg/.3mL
Injection, solutionIntravenous; Subcutaneous40 mg/.4mL
Injection, solutionIntravenous; Subcutaneous60 mg/.6mL
Injection, solutionIntravenous; Subcutaneous80 mg/.8mL
InjectionIntravenous; Subcutaneous100 mg/mL
InjectionIntravenous; Subcutaneous120 mg/.8mL
InjectionIntravenous; Subcutaneous150 mg/mL
InjectionIntravenous; Subcutaneous30 mg/.3mL
InjectionIntravenous; Subcutaneous300 mg/3mL
InjectionIntravenous; Subcutaneous40 mg/.4mL
InjectionIntravenous; Subcutaneous60 mg/.6mL
InjectionIntravenous; Subcutaneous80 mg/.8mL
SolutionSubcutaneous100 mg
SolutionSubcutaneous30 mg
SolutionSubcutaneous40 mg
SolutionSubcutaneous60 mg
SolutionSubcutaneous80 mg
SolutionSubcutaneous120 mg
SolutionSubcutaneous150 mg
SolutionSubcutaneous90 mg
SolutionIntravenous; Subcutaneous100 mg
Prices
Unit descriptionCostUnit
Lovenox 300 mg/3ml Solution 3ml Vial281.47USD vial
Lovenox 150 mg/ml Solution 1ml Syringe140.94USD syringe
Lovenox 100 mg/ml Solution 1ml Syringe93.93USD syringe
Lovenox 80 mg/0.8ml Solution 0.8ml Syringe75.14USD syringe
Lovenox 60 mg/0.6ml Solution 0.6ml Syringe56.36USD syringe
Lovenox 40 mg/0.4ml Solution 0.4ml Syringe37.53USD syringe
Lovenox Hp (0.8Ml/1Ml Syringe) 150 mg/ml Syringe34.63USD syringe
Lovenox 30 mg/0.3ml Solution 0.3ml Syringe28.15USD syringe
Lovenox (0.4 - 1 Ml Syringe) 100 mg/ml Syringe23.09USD syringe
Lovenox 100 mg/ml23.09USD syringe
Lovenox (0.3 Ml Syringe) 30 mg/syr Syringe6.97USD syringe
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2045433 No2002-07-302011-06-25Canada
US5389618 No1995-02-142012-02-14Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility> 200 mg/mLNot Available
logP-13.2Not Available
Predicted PropertiesNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Taxonomy
ClassificationNot classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
potentiator
General Function:
Serine-type endopeptidase inhibitor activity
Specific Function:
Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin, matriptase-3/TMPRSS7, as well as factors IXa, Xa and XIa. Its inhibitory activity is greatly enhanced in the presence of heparin.
Gene Name:
SERPINC1
Uniprot ID:
P01008
Molecular Weight:
52601.935 Da
References
  1. Peng K, Wang C, Pang BS, Yang YH: [Effects of thrombolysis and anticoagulation on the functions of vascular endothelial cells and coagulation and fibrinolysis in patients with pulmonary thromboembolism]. Zhonghua Jie He He Hu Xi Za Zhi. 2005 Sep;28(9):596-9. [PubMed:16207425 ]
  2. Lee S, Gibson CM: Enoxaparin in acute coronary syndromes. Expert Rev Cardiovasc Ther. 2007 May;5(3):387-99. [PubMed:17489664 ]
  3. Bisio A, Vecchietti D, Citterio L, Guerrini M, Raman R, Bertini S, Eisele G, Naggi A, Sasisekharan R, Torri G: Structural features of low-molecular-weight heparins affecting their affinity to antithrombin. Thromb Haemost. 2009 Nov;102(5):865-73. doi: 10.1160/TH09-02-0081. [PubMed:19888521 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serine-type endopeptidase activity
Specific Function:
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name:
F10
Uniprot ID:
P00742
Molecular Weight:
54731.255 Da
References
  1. Graff J, Picard-Willems B, Harder S: Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a. Int J Clin Pharmacol Ther. 2007 Apr;45(4):237-43. [PubMed:17474542 ]
  2. Berges A, Laporte S, Epinat M, Zufferey P, Alamartine E, Tranchand B, Decousus H, Mismetti P: Anti-factor Xa activity of enoxaparin administered at prophylactic dosage to patients over 75 years old. Br J Clin Pharmacol. 2007 Oct;64(4):428-38. Epub 2007 May 17. [PubMed:17509040 ]
  3. Sanchez-Pena P, Hulot JS, Urien S, Ankri A, Collet JP, Choussat R, Lechat P, Montalescot G: Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. Br J Clin Pharmacol. 2005 Oct;60(4):364-73. [PubMed:16187968 ]
  4. Dalmora SL, Junior LB, Schmidt CA, Vaccari SF, Oliveira PR, Codevilla CF: Validation of the anti-factor Xa assay for the potency assessment of enoxaparin in pharmaceutical formulations. J AOAC Int. 2004 Nov-Dec;87(6):1305-8. [PubMed:15675440 ]
  5. Paige JT, Gouda BP, Gaitor-Stampley V, Scalia PG, Klainer TE, Raum WJ, Martin LF: No correlation between anti-factor Xa levels, low-molecular-weight heparin, and bleeding after gastric bypass. Surg Obes Relat Dis. 2007 Jul-Aug;3(4):469-75. Epub 2007 Jun 12. [PubMed:17567541 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
Other
General Function:
Peroxidase activity
Specific Function:
Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.
Gene Name:
MPO
Uniprot ID:
P05164
Molecular Weight:
83867.71 Da
References
  1. Rudolph TK, Rudolph V, Witte A, Klinke A, Szoecs K, Lau D, Heitzer T, Meinertz T, Baldus S: Liberation of vessel adherent myeloperoxidase by enoxaparin improves endothelial function. Int J Cardiol. 2010 Apr 1;140(1):42-7. doi: 10.1016/j.ijcard.2008.10.035. Epub 2008 Dec 2. [PubMed:19049846 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23